Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Medtronic Terminate AF Study

NCT03546374 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal atrial fibrillation (AF).

Interventions

  • PROCEDURE Surgical Ablation
  • DEVICE Cardioblate and Cryoflex hand held devices

Study Locations (15)

Washington

  • Virginia Mason Heart Institute — Seattle
  • Swedish Medical Center — Seattle
  • St. Joseph Medical Center — Tacoma

California

  • Stanford Hospitals and Clinic — Palo Alto
  • Adventist Health St. Helena — St. Helena

Pennsylvania

  • Allegheny General Hospital — Pittsburgh
  • Lankenau Medical Center — Wynnewood

Connecticut

  • Hartford Healthcare — Hartford

Indiana

  • St Vincent Heart Center of Indiana — Indianapolis

Massachusetts

  • Massachusetts General Hospital — Boston

Michigan

  • Corewell Health — Grand Rapids

Missouri

  • Washington University School of Medicine — St Louis

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2018-11-15
Est. Completion 2026-12
Phase NA

Sponsor

Medtronic Cardiac Surgery

7 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03546374

The ClinicalTrials.gov registry entry for NCT03546374 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Surgery, which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Persistent Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions — of which Surgical Ablation is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03546374 reports 15 study locations spanning 11 distinct geographic areas — top geographies include Washington, California, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03546374 about?

NCT03546374 is a clinical study titled "Medtronic Terminate AF Study". The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of non-paroxysmal atrial fibrillation (AF).

What is the current status of trial NCT03546374?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2018-11-15. Estimated completion is 2026-12.

What conditions does trial NCT03546374 study?

This clinical trial studies the following conditions: Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03546374?

The interventions under investigation include: Surgical Ablation (PROCEDURE), Cardioblate and Cryoflex hand held devices (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03546374?

This trial is sponsored by Medtronic Cardiac Surgery, which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03546374 being conducted?

This trial has 15 study locations across California, Connecticut, Indiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial